On August 6, 2026, a Phase 3 trial involving retatrutide entered recruiting status. The trial, titled "A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)," is registered under identifier NCT07165028.
This is a master protocol study, meaning it is designed to evaluate multiple agents within a shared trial framework for adults with metabolic dysfunction-associated steatotic liver disease, commonly known as MASLD. Retatrutide is listed among the agents being studied under this protocol.
The trial is currently in Phase 3 and its recruitment status is listed as recruiting. No results have been posted for this trial at this time. The event data does not include information about specific outcomes, efficacy, or safety findings, as the trial is still in the recruitment phase.
Further details about the trial design, eligibility criteria, and enrollment can be found through the official clinical trial registry listing. As with any active clinical trial, updates on status, enrollment completion, or results would be expected as the study progresses through its phases.
Readers interested in learning more about retatrutide generally can consult the compound overview for additional context.